Stock Forecast

  LAVA Therapeutics N.V. ( LVTX) Stock. Should you Buy or Sell?    $ 2.50

-0.19 (-8.23 %)



LAVA Therapeutics N.V. Analysis

Updated on 10-09-2022
Symbol LVTX
Price $2.50
Beta 0.000
Volume Avg. $6.36 thousand
Market Cap $64.44 M
52 Week Range $2.28 - $8.38


LAVA Therapeutics N.V. opened the day at $2.50 which is -8.23 % on yesterday's close. LAVA Therapeutics N.V. has a 52 week high of $8.38 and 52 week low of $2.28, which is a difference of $6.1. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $64.44 M and total net profit is $5000000 which means the company is trading at 12.89 times profit to market capitalization. Theoretically, if you were to buy LAVA Therapeutics N.V. for $64.44 M, it would take 15 years to get your money back. LAVA Therapeutics N.V. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.



Price Chart


1 D | All


Financials




LAVA Therapeutics N.V. Stock Forecast - Is LAVA Therapeutics N.V. a Buy or Sell?


DCF ScoreStrong Buy
ROE ScoreNeutral
ROA ScoreNeutral
DE ScoreNeutral
PE ScoreSell
PB ScoreStrong Buy
Overall RecommendationBuy

Growth and Value


PE Ratio 0.263
Dividend Yiel 0.000
Net Profit Margin -7.743


Valuing LAVA Therapeutics N.V.


Price Book Value Ratio 0.594 Price To Book Ratio 0.594
Price To Sales Ratio 12.687 Price Earnings Ratio -1.639


How liquid is LAVA Therapeutics N.V.


Current Ratio 7.754
Quick Ratio 7.654


Debt


Debt Ratio 0.163 Debt Equity Ratio 0.195
Long Term Debt To Capitalization 0.042 Total Debt To Capitalization 0.045



Latest news about LAVA Therapeutics N.V.


LAVA Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

UTRECHT, The Netherlands and PHILADELPHIA, Sept. 07, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will present in a virtual format at the H.C. Wainwright 24th Annual Global Investment Conference being held virtually and in New York City.

Date : 07/09/2022

LAVA Therapeutics to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

LAVA Therapeutics to host clinical results conference call and webcast on June 16 at 8:00 a.m. EDT/2:00 p.m. CEST LAVA Therapeutics to host clinical results conference call and webcast on June 16 at 8:00 a.m. EDT/2:00 p.m. CEST

Date : 01/06/2022

Why LAVA Therapeutics (LVTX) Might Surprise This Earnings Season

LAVA Therapeutics (LVTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Date : 16/05/2022

LAVA Therapeutics to Participate at the UBS Global Healthcare Conference

UTRECHT, The Netherlands and PHILADELPHIA, May 05, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will participate in a fireside chat at the UBS Global Healthcare Conference 2022 being held in New York, NY.

Date : 05/05/2022

LAVA Therapeutics to Present Updated LAVA-051 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

UTRECHT, The Netherlands and PHILADELPHIA, April 27, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced the Company will present updated interim data from the dose escalation phase of the ongoing Phase 1/2a clinical trial of LAVA-051 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago and virtually June 3-7, 2022.

Date : 27/04/2022





About LAVA Therapeutics N.V.


CEO : Mr. Stephen Allen Hurly
Sector : Healthcare
Industry : Biotechnology

Website : https://www.lavatherapeutics.com

Exchange : NASDAQ Global Select

Description :

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.


My Newsletter

Sign Up For Updates & Newsletters